EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Yoko Takatsuna iD, Ryoichi Ishibashi, Masaya Koshizaka iD, Tomoaki Tatsumi iD, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote

Journal of Diabetes Investigation · 2026

DOI: 10.1111/jdi.70330 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Yoko Takatsuna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taisho Toyama Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular edema (DMO) via post hoc subgroup analysis. Previous findings were derived exclusively from observational studies, and no interventional trials based on protocol‐defined criteria had been conducted. Materials and Methods Based on the COMET trial data, this post hoc analysis targeted mild DME cases, defined by baseline central retinal thickness (CRT) ≤375 μm and best‐corrected visual acuity (BCVA) ≤0.155 (logMAR). Patients were randomized to SGLT2i (luseogliflozin) or sulfonylurea (SU, glimepiride) groups. Mild subgroups were compared with the corresponding non‐mild cases. The primary outcome was the 48‐week frequency of intravitreal ranibizumab injections (IVRs).

Results

In the CRT ≤375 μm subgroup, IVR frequency was significantly lower with SGLT2i vs SU (mean 0.5 ± 1.0 vs 4.3 ± 0.8; P = 0.005, adjusted ancova . Cohen's d of 2.1). The cumulative mean number of IVRs was significantly lower in the SGLT2i group than in the SU group ( P = 0.004, hazard ratio 0.29, 95% confidence interval 0.12–0.67). In the BCVA ≤ 0.155 subgroup, whose mean CRT exceeded 400 μm, no significant difference in IVR frequency was observed between the SGLT2i‐treated and SU‐treated patients. In addition, no intergroup differences were found in patients outside the mild subgroups.

Conclusions

In this exploratory analysis, SGLT2 inhibition was associated with fewer intravitreal injections in patients meeting the CRT‐based mild criteria. These findings are hypothesis‐generating and warrant confirmation in future prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathySodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2SorbitolHumansFemaleMaleIntravitreal InjectionsMiddle AgedSulfonylurea CompoundsRanibizumabVisual AcuityAgedPrognosisTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

Anti‐VEGF injectionDiabetic macular edemaSodium–glucose cotransporter 2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsglimepirideRanibizumabSorbitol

Autor:innen und Institutionen

  • Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan.
  • Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Department of Endocrinology, Haematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.

ORCID-Profile: Yoko Takatsuna, Masaya Koshizaka, Tomoaki Tatsumi

Förderung

  • Taisho Toyama Pharmaceutical Company

Zitieren

APA

Takatsuna, Y., Ishibashi, R., Koshizaka, M., Tatsumi, T., Baba, T., Yamamoto, S., & Yokote, K. (2026). Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70330

Vancouver

Takatsuna Y, Ishibashi R, Koshizaka M, Tatsumi T, Baba T, Yamamoto S, et al. Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70330

BibTeX
@article{Takatsuna2026,
  author = {Takatsuna, Yoko and Ishibashi, Ryoichi and Koshizaka, Masaya and Tatsumi, Tomoaki and Baba, Takayuki and Yamamoto, Shuichi and Yokote, Koutaro},
  title = {Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70330}
}
Kostenlos starten →